Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
35700412
PubMed Central
PMC9384955
DOI
10.1200/po.21.00525
Knihovny.cz E-resources
- MeSH
- Aminopyridines MeSH
- Lymphoma, Large-Cell, Anaplastic * drug therapy MeSH
- Lactams MeSH
- Humans MeSH
- Lactams, Macrocyclic MeSH
- Pyrazoles therapeutic use MeSH
- Neoplasm, Residual MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Aminopyridines MeSH
- Lactams MeSH
- lorlatinib MeSH Browser
- Lactams, Macrocyclic MeSH
- Pyrazoles MeSH
Central European Institute of Technology Masaryk University Brno Czech Republic
Clinical Pharmacy Section of Hospital Pharmacy University Hospital Brno Brno Czech Republic
CSTS Health Care Toronto ON Canada
Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic
Department of Laboratory Methods Faculty of Medicine Masaryk University Brno Czech Republic
Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic
International Clinical Research Center St Anne's University Hospital Brno Czech Republic
See more in PubMed
Turner SD, Lamant L, Kenner L, et al. Anaplastic large cell lymphoma in paediatric and young adult patients. Br J Haematol. 2016;173:560–572. PubMed
Brugières L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children—A report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11:53–58. PubMed
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–1703. PubMed PMC
Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A Children's Oncology Group study. J Clin Oncol. 2017;35:3215–3221. PubMed PMC
Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib. N Engl J Med. 2016;374:95–96. PubMed
Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics. 2010;4:315–323. PubMed PMC
Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer. Clin Cancer Res. 2012;18:1472–1482. PubMed PMC
Amin AD, Rajan SS, Liang WS, et al. Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK+ tumors. Cancer Res. 2015;75:2916–2927. PubMed PMC
Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: Results of COG trial ANHL12P1. Blood. 2021;137:3595–3603. PubMed PMC
Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27:5056–5061. PubMed
Goldsmith KC, Kayser K, Groshen SG, et al. Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma consortium study. J Clin Oncol. 2020;38 suppl 15; abstr 10504.
Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphoma. Blood. 2007;110:670–677. PubMed
Rajan SS, Amin AD, Li L, et al. The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. Oncogene. 2020;39:2103–2117. PubMed PMC
Bloomfield M, Kanderová V, Paračková Z, et al. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol. 2018;38:589–601. PubMed
Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 2011;12:1004–1012. PubMed PMC
Trigg RM, Turner SD. ALK in neuroblastoma: Biological and therapeutic implications. Cancers (Basel) 2018;10:E113. PubMed PMC
Verma P, Jain S, Kapoor G. Complete response with crizotinib in two children with chemotherapy resistant neuroblastoma. South Asian J Cancer. 2017;6:89–90. PubMed PMC
Foyil KV, Bartlett NL. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J. 2012;18:450–456. PubMed
Laneuville P. When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Curr Treat Options Oncol. 2018;19:15. PubMed PMC
Sabnis HS, Keenum C, Lewis RW, et al. Growth disturbances in children and adolescents receiving long‐term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. Br J Haematol. 2019;185:795–799. PubMed
Algazi AP, Othus M, Daud AI, et al. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: A randomized phase 2 trial. Nat Med. 2020;26:1564–1568. PubMed PMC
Lee Y, Choi YR, Kim KY, et al. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation. Oncotarget. 2016;7:43315–43323. PubMed PMC
Klement GL. Eco-evolution of cancer resistance. Sci Transl Med. 2016;8:327fs5. PubMed
Enriquez-Navas PM, Kam Y, Das T, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 2016;8:327ra24. PubMed PMC
Gatenby RA, Brown J, Vincent T. Lessons from applied ecology: Cancer control using an evolutionary double bind. Cancer Res. 2009;69:7499–7502. PubMed
